OPTITHERA Inc. was founded in 2014 by two professors of Université de Montréal, Johanne Tremblay and Pavel Hamet (Canada Research Chair in Predictive Genomics). The company aims at becoming an important hub in the Precision Medicine market of diabetes and its complications.


With public/private investments of more than 20M$, the company created a comprehensive database that includes whole genome genotyping, phenotypic and outcome data collected in thousands of patients with T2 diabetes over a period of 10 years and used as an inference cohort for determination of the polygenic risk score (PRS) of each patient to develop diabetes complications.


PRS for renal and cardiovascular complications of diabetes are the first Precision tools developed by OPTITHERA ready for distribution. These PRS are also offered to Pharma companies to select high risk patients for FDA-required safety trials of novel anti-diabetic drugs.


Our goal is to develop Precision Medicine tools to allow physicians to better personalize healthcare for their patients


To deliver the promises of Precision Medicine to each and every patient with type 2 diabetes around the world.


Founding President of OPTITHERA & Chief Medical Officer


Dr. Hamet holds a Canada Research Chair in Predictive Genomics. He is Professor of Medicine at Université de Montréal, Adjunct Professor of Experimental Medicine at McGill University, and Visiting Professor at the First Faculty of Medicine at Charles University, Prague, Czech Republic.


He founded and directed the CHUM Research Centre (CRCHUM) from 1996 to 2006. He is currently Chief of Gene Medicine at CHUM. He is the author of more than 600 scientific publications in diabetes and hypertension and is recognized as an international leader in personalized medicine of cardiometabolic diseases.

Johanne Tremblay, PhD, FAHA, FCAHS
Co-founder, Vice-President and Chief Scientific Officer


Professor of Medicine at Université de Montréal & fellow of the Canadian Academy of Health Sciences and of the American Heart Association, she authored more than 300 scientific publications and holds several patents in the area of diabetes, cardiovascular diseases and PM. She chaired the programme committees of First and Second Congress of Personalized healthcare in Montreal with participation of scientists from over 25 countries.

Martin Godbout, OC, PhD
Chief Executive Officer of OPTITHERA


Following a formative academic career at Laval University in the early 90’s, Martin Godbout was named President and general manager of Société Innovatech Québec, a technology venture capital fund (60 M$). In 1997, he became the executive VP of BioCapital II, a biopharmaceutical venture fund (60M$). In May 2000, he became the President and CEO of Genome Canada, for the next 10 years (1.4 B$). In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of ten nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world”.

Pierre Dumas, PhD
Administrative Director


With more than 18 years of experience in clinical and basic research, Pierre Dumas has worked on large scale projects in the United States (NHLBI SCOR and PGA programs) and Canada (CFI, Genome Quebec and CART@GENE). He has a long-standing experience in management of high throughput facilities with experience ranging from budgets, contracts and RS&DE tax credits to ethics board application. He is experienced in all phases of clinical research. Pierre holds a Ph.D. (biomedical sciences) from University of Montreal and completed four years of post-doctoral training in cardiovascular genetics at the Medical College of Wisconsin and at McGill University.

Candan Hizel Perry, PhD
Pharmacogenetics Director


Dr. Hizel has more than 17 years of experience in personalized medicine, including pharmacogenomics (PGx) association studies, biomarker research, clinical diagnostics, health communications, health information technology, health behaviour changes and health systems improvement in both high-income country (HIC) and in low-and middle-income country (LMIC) settings. Between 1999 and 2005, he was research director and vice-president within the R&D department of a genomics/PGx bioinformatics consulting company in Clermont-Fd/France and in Montreal/Canada, respectively. 


December 12 2019
Congrès InnovAction au @CHUM
Conférence sur la médecine personnalisé...
November 21 2019
Polygenic risk: What’s the score?
Researchers are improving risk prediction [NATURE]...
November 1 2019
Polygenic risk scores predict diabetic complications and their response to therapy
Type 2 diabetes increases the risk of cardiovascular and renal complications, but early risk prediction can lead to timely intervention and better...